Jeffrey P. Hodge

2.9k total citations · 2 hit papers
39 papers, 2.3k citations indexed

About

Jeffrey P. Hodge is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cell Biology. According to data from OpenAlex, Jeffrey P. Hodge has authored 39 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Cell Biology. Recurrent topics in Jeffrey P. Hodge's work include Microtubule and mitosis dynamics (11 papers), Cancer Treatment and Pharmacology (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Jeffrey P. Hodge is often cited by papers focused on Microtubule and mitosis dynamics (11 papers), Cancer Treatment and Pharmacology (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Jeffrey P. Hodge collaborates with scholars based in United States, United Kingdom and Netherlands. Jeffrey P. Hodge's co-authors include Jia Xin Yu, Vanessa M. Hubbard-Lucey, Jun Tang, Samik Upadhaya, Cristina Oliva, A. Benjamin Suttle, Yunqing Lin, Mohammed M. Dar, Lini Pandite and Joanne Lager and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and Clinical Cancer Research.

In The Last Decade

Jeffrey P. Hodge

38 papers receiving 2.2k citations

Hit Papers

The clinical trial landsc... 2018 2026 2020 2023 2018 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
    2018 301 citations Jun Tang, Jia Xin Yu et al. Nature Reviews Drug Discovery profile →
  2. Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
    2022 134 citations Samik Upadhaya, Jeffrey P. Hodge et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey P. Hodge United States 20 1.3k 794 566 400 252 39 2.3k
Susan Galbraith United States 23 1.1k 0.9× 957 1.2× 523 0.9× 228 0.6× 108 0.4× 45 2.9k
Enzo Galligioni Italy 30 1.7k 1.4× 1.1k 1.3× 1.2k 2.1× 198 0.5× 207 0.8× 166 3.5k
Albiruni R. Abdul Razak Canada 29 2.0k 1.6× 1.1k 1.4× 1.1k 2.0× 639 1.6× 73 0.3× 96 3.5k
Manon Huizing Belgium 29 2.2k 1.8× 664 0.8× 457 0.8× 95 0.2× 100 0.4× 98 3.0k
Carl Plager United States 32 2.4k 1.9× 1.1k 1.4× 1.2k 2.2× 833 2.1× 71 0.3× 71 3.7k
Hendrik‐Tobias Arkenau United Kingdom 34 2.3k 1.8× 1.5k 1.9× 1.2k 2.1× 362 0.9× 116 0.5× 214 4.1k
Urban Emmenegger Canada 32 1.5k 1.2× 1.3k 1.7× 923 1.6× 463 1.2× 79 0.3× 150 3.4k
Leonard J. Appleman United States 29 1.5k 1.2× 1.3k 1.7× 1.2k 2.1× 761 1.9× 69 0.3× 178 3.3k
Anna Spreafico Canada 31 2.3k 1.9× 1.2k 1.6× 1.2k 2.1× 567 1.4× 107 0.4× 229 3.8k
Stéphane Culine France 34 1.6k 1.3× 1.4k 1.7× 2.0k 3.5× 206 0.5× 143 0.6× 163 4.6k

Countries citing papers authored by Jeffrey P. Hodge

Since Specialization
Citations

This map shows the geographic impact of Jeffrey P. Hodge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey P. Hodge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey P. Hodge more than expected).

Fields of papers citing papers by Jeffrey P. Hodge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey P. Hodge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey P. Hodge. The network helps show where Jeffrey P. Hodge may publish in the future.

Co-authorship network of co-authors of Jeffrey P. Hodge

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey P. Hodge. A scholar is included among the top collaborators of Jeffrey P. Hodge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey P. Hodge. Jeffrey P. Hodge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Upadhaya, Samik, et al.. (2022). Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nature Reviews Drug Discovery. 21(7). 482–483. 134 indexed citations breakdown →
2.
Upadhaya, Samik, et al.. (2020). Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. Nature Reviews Drug Discovery. 20(3). 168–169. 123 indexed citations
3.
Tang, Jun, et al.. (2018). The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nature Reviews Drug Discovery. 17(12). 854–855. 301 indexed citations breakdown →
4.
Yu, Xinyan, et al.. (2018). Using real world data to evaluate overall survival in PD1-treated vs. standard of care metastatic melanoma patients.. Journal of Clinical Oncology. 36(15_suppl). e21606–e21606. 2 indexed citations
5.
6.
Jonge, Maja J.A. de, Paul Hamberg, Jaap Verweij, et al.. (2012). Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Investigational New Drugs. 31(3). 751–759. 29 indexed citations
7.
Holen, Kyle D., Chandra P. Belani, George Wilding, et al.. (2010). A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemotherapy and Pharmacology. 67(2). 447–454. 60 indexed citations
8.
9.
Heath, Elisabeth I., E. Gabriela Chiorean, Christopher J. Sweeney, et al.. (2010). A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors. Clinical Pharmacology & Therapeutics. 88(6). 818–823. 85 indexed citations
10.
Friedländer, Michael, Kenneth C. Hancock, Danny Rischin, et al.. (2010). A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology. 119(1). 32–37. 171 indexed citations
11.
Burris, Howard A., Suzanne F. Jones, Daphne Williams, et al.. (2010). A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Investigational New Drugs. 29(3). 467–472. 52 indexed citations
12.
Yau, CC, Pei‐Jer Chen, C. Martin Curtis, et al.. (2009). A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology. 27(15_suppl). 3561–3561. 19 indexed citations
13.
Blagden, Sarah P., L. Rhoda Molife, Miranda Payne, et al.. (2008). A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. British Journal of Cancer. 98(5). 894–899. 63 indexed citations
14.
Kathman, Steven J., et al.. (2008). A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression. Cancer Chemotherapy and Pharmacology. 63(3). 469–476. 12 indexed citations
15.
Kathman, Steven J., et al.. (2006). A Bayesian Population PK–PD Model of Ispinesib-induced Myelosuppression. Clinical Pharmacology & Therapeutics. 81(1). 88–94. 18 indexed citations
16.
Gerskowitch, V.P., Jeffrey P. Hodge, Robert A. D. Hull, et al.. (2006). Unexpected relationship between plasma protein binding and the pharmacodynamics of 2‐NAP, a CCK1‐receptor antagonist. British Journal of Clinical Pharmacology. 63(5). 618–622. 8 indexed citations
17.
Blagden, Sarah P., R. Molife, Miranda Payne, et al.. (2005). Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors.. Clinical Cancer Research. 11. 1 indexed citations
18.
Kurtzberg, Joanne, T J Ernst, Michael J. Keating, et al.. (2005). Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies. Journal of Clinical Oncology. 23(15). 3396–3403. 129 indexed citations
19.
Burris, Howard A., Patricia LoRusso, Suzanne F. Jones, et al.. (2004). Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. Journal of Clinical Oncology. 22(14_suppl). 2004–2004. 25 indexed citations
20.
Kisor, David F., William Plunkett, Joanne Kurtzberg, et al.. (2000). Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies. Journal of Clinical Oncology. 18(5). 995–995. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan Galbraith Breakdown of academic impact, for papers by Enzo Galligioni Breakdown of academic impact, for papers by Albiruni R. Abdul Razak Breakdown of academic impact, for papers by Manon Huizing Breakdown of academic impact, for papers by Carl Plager Breakdown of academic impact, for papers by Hendrik‐Tobias Arkenau Breakdown of academic impact, for papers by Urban Emmenegger Breakdown of academic impact, for papers by Leonard J. Appleman Breakdown of academic impact, for papers by Anna Spreafico Breakdown of academic impact, for papers by Stéphane Culine
Rankless by CCL
2026